Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kaolin + pectin is a **combination oral medication** historically used for the **treatment of mild to moderate diarrhea** in humans and animals. Kaolin is a fine clay (hydrated aluminum silicate) that acts as an **adsorbent**, binding substances in the gastrointestinal tract, thereby reducing stool frequency and improving stool consistency. Pectin, a plant-derived polysaccharide, forms a gelatinous mass in the GI tract, enhancing the binding and bulk-forming effects. The combination works **locally in the gut**: kaolin adsorbs bacteria and toxins, while pectin soothes irritated intestinal mucosa and increases stool bulk. This combination does **not have intrinsic antibacterial activity** and is ineffective against infections with fever or bloody stool. The mechanism is non-systemic, with minimal absorption. The use of this combination for diarrhea in humans is **no longer FDA-approved in the US as of 2004**, but it is still found in veterinary products and some over-the-counter formulations in other regions[1][5][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kaolin + pectin.